A Double-Blind, Randomized, Placebo-Controlled, Sequential, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs VBY 036 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 05 Aug 2013 New trial record
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.